In Brief
Refine Search
Biotechnology
Japanese drugmaker Eisai today that the humanized antisoluble aggregated amyloid-beta (Aβ) monoclonal antibody Leqembi (lecanemab) has been launched in South Korea. 28 November 2024
Pharmaceutical
UK-based immunotherapy firm Centauri Therapeutics has secured a £1 million ($1.25 million) grant from PACE (Pathways to Antimicrobial Clinical Efficacy) to further develop its Alphamer technology. 25 November 2024
Biotechnology
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash. 23 November 2024
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Biotechnology
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
Biotechnology
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Biotechnology
Sirnaomics, a firm specializing in RNAi therapeutics, has entered into a subscription agreement with biotech specialist Poon Hung Fai. 4 October 2024
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
article
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has elected Bruno Sepodes as its new chair. 19 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Biotechnology
US biotech major Gilead Sciences this morning announced that it has entered into a definitive agreement pursuant to which Gilead will acquire MiroBio for approximately $405 million in cash, subject to customary adjustments. 4 August 2022
Pharmaceutical
German life sciences major Bayer beat consensus estimates with its sales in the second quarter of 2022, with the 12.82 billion euros ($13 billion) total representing an 18% rise on the same period in 2021. 4 August 2022
Pharmaceutical
A new report by stakeholder intelligence firm alva has revealed the leaders in the pharma industry when it comes to equality, diversity and inclusion (EDI)—and Bayer tops the list. 4 August 2022
Biotechnology
Bermuda-based Kiniksa Pharmaceuticals has announced a global license agreement with Swiss pharma giant Roche and its US subsidiary Genentech, for the rights to develop and commercialize vixarelimab, a fully human monoclonal antibody targeting oncostatin M receptor beta (OSMRβ). 4 August 2022
Pharmaceutical
The age-related macular degeneration (AMD) market in the seven major markets (7MM: the USA, France, Germany, Italy, Spain, the UK, and Japan) is set to grow from $7.3 billion in 2021 to $22.8 billion in 2031, driven by the longer-acting anti-vascular endothelial growth factor (VEGF) pipeline therapies as well as potentially first-to-market therapies for geographic atrophy (GA). 4 August 2022
Pharmaceutical
German life sciences and pharma firm Merck KGaA today posted financial results for first-half 2022, showing that net sales increased by 14.3% compared with the second quarter of 2021 to 5,568 million euros ($5.64 billion). 4 August 2022
Pharmaceutical
Privately-held Danish dermatology specialist LEO Pharma has announced the appointment of Sven Hauptmann as its new executive vice president of global product supply. 4 August 2022
Pharmaceutical
Reporting financial results for the first half of 2022 late yesterday, Danish diabetes care giant Novo Nordisk (NOV: N) said that sales increased by 25% in Danish kroner and by 16% at constant exchange rates to 83.3 billion kroner ($11.4 billion) in the six months. 4 August 2022
Pharmaceutical
F2G, a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat life-threatening rare fungal infections, has announced a $70 million financing. 4 August 2022
Biotechnology
US RNAi therapeutics pioneer Alnylam Pharmaceuticals looked set to close Wednesday’s New York trading with gains in excess of 40%. 3 August 2022
Biotechnology
US biotech major Gilead Sciences is trading 7% higher during Wednesday’s late morning trading in New York after presenting its financial results for the second quarter of 2022. 3 August 2022
Biotechnology
Shares of San Diego, USA-based biotech Poseida Therapeutics were up almost 98% at $4.80 late morning, after it announced it has entered into a broad strategic collaboration and license agreement with Swiss pharm giant Roche, focused on developing allogeneic CAR-T therapies directed to hematologic malignancies. 3 August 2022
Biotechnology
US pharma giant Merck & Co and Japan’s Eisai today announced that the Phase III LEAP-002 trial investigating Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, plus Lenvima (lenvatinib), the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, versus Lenvima monotherapy did not meet its dual primary endpoints of overall survival (OS) and progression-free survival (PFS) as a first-line treatment for patients with unresectable hepatocellular carcinoma (uHCC). 3 August 2022
Biotechnology
Eliem Therapeutics, an Anglo-American biotech focused on developing therapies for neuronal excitability disorders, has reported results from its Phase IIa trial investigating ETX-810 for the treatment of lumbosacral radicular pain (LSRP). 3 August 2022
Pharmaceutical
HERA, the European Commission’s Health Preparedness and Response Authority, has signed a joint procurement framework contract with the Spanish company HIPRA Human Health for the supply of its protein COVID-19 vaccine. 3 August 2022
Pharmaceutical
A feature on renewed interest in an area where the difficulty for drugmakers is matched only by the potential rewards. 3 August 2022
Pharmaceutical
French drugmaker Ipsen saw its shares drop as much as 5% in early trading today, as it announced that the Phase III RESILIENT trial did not meet its primary endpoint of overall survival (OS) compared to topotecan. 3 August 2022
Biotechnology
US biotech Rigel Pharmaceuticals and Forma Therapeutics have entered into an exclusive, worldwide license agreement to develop, manufacture and commercialize olutasidenib, an oral, small molecule inhibitor of mIDH1 being investigated for the treatment of relapsed/refractory acute myeloid leukemia (R/R AML) and other malignancies. 3 August 2022
Biosimilars
Yesterday, the US Food and Drug Administration approved Cimerli (ranibizumab-eqrn; FY201) injection, as biosimilar to, and interchangeable with, Lucentis (ranibizumab injection). This is the 37th biosimilar approval in the USA, the agency noted. 3 August 2022
Biotechnology
Swiss biotech AC Immune (Nasdaq: ACIU) on Tuesday announced that its partners presented the first quantitative data from the Alzheimer’s Prevention Initiative (API) Autosomal Dominant Alzheimer's Disease (ADAD) Colombia Trial during a Focused Topic Session at the Alzheimer’s Association International Conference (AAIC). 3 August 2022
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze